Contact us
 |
[email protected] |
 |
3275638434 |
 |
 |
| Paper Publishing WeChat |
Useful Links
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Article
Chitosan: A Desirable Candidate for Treating Hyperphosphatemia?
Author(s)
Haisong Zhang, Meng Yu and Hailei Zhang
Full-Text PDF
XML 705 Views
DOI:10.17265/2328-2150/2016.02.006
Affiliation(s)
ABSTRACT
Non-absorbed macromolecular binders as sequestrants for phosphate ions offer an effective approach to treat hyperphosphatemia in ESRD (end-stage renal disease) patients. RenaGel® has been an example with remarkable success of a polymer synthesized to prevent the absorption of dietary phosphate for ESRD patients. Electrostatic interaction is the primary driving force for complexation of phosphate-based anions with these amino groups in the polymer backbone. Chitosan is a deacetylation product of chitin, which is the structural element in the exoskeleton of crustaceans and cell walls of fungi. The amino groups in the backbone give the phosphate binding ability to chitosan. This article has demonstrated that chitosan exhibited a phosphate binding effect indeed. Thus, it has potential applications in environmental management and wastewater treatment, as well as treatment of hyperphosphatemia patients.
KEYWORDS
Chitosan, phosphate binder, hyperphosphatemia.
Cite this paper
Zhang, H., Yu, M., and Zhang, H. 2016. “Chitosan: A Desirable Candidate for Treating Hyperphosphatemia?” Journal of Pharmacy and Pharmacology 4 (2): 99-104.
References